WGS
The table below shows GeneDx Holdings Corp.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $427.54M | $305.45M | $202.57M | $234.69M | $212.19M | $179.32M |
| Cost of revenue | $129.37M | $111.05M | $112.56M | $261.44M | $228.80M | $175.30M |
| Gross profit | $298.17M | $194.40M | $90.01M | -$26.75M | -$16.60M | $4.03M |
| R&D | $72.03M | $45.72M | $58.27M | $86.20M | $105.16M | $72.70M |
GeneDx Holdings Corp. reported annual revenue of $427.54M for fiscal year 2025. That is up 40.0% from $305.45M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $196.17M (FY 2019) to $427.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $150.82M | $104.52M | $139.02M | $216.17M | $205.99M | $100.74M |
| Operating income | -$13.08M | -$23.21M | -$180.60M | -$667.65M | -$446.15M | -$241.99M |
| Income tax | -$116.00K | -$343.00K | -$926.00K | -$49.05M | $0.00 | $0.00 |
| Net income | -$21.00M | -$52.30M | -$175.80M | -$548.98M | -$245.39M | -$241.34M |
| EPS (diluted) | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$2.27 | -$47.04K |